Published in PLoS One on July 03, 2017
NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41
Phenotypic and functional features of human Th17 cells. J Exp Med (2007) 11.33
Induction and effector functions of T(H)17 cells. Nature (2008) 7.75
Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med (1998) 7.24
Active induction of experimental allergic encephalomyelitis. Nat Protoc (2006) 3.64
CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol (2008) 3.51
CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol (1999) 3.32
Dynamic regulatory network controlling TH17 cell differentiation. Nature (2013) 3.07
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol (2007) 2.85
Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum (2009) 2.80
CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood (2004) 2.80
T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol (2009) 2.65
An overview of IL-17 function and signaling. Cytokine (2008) 2.38
Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med (1995) 2.24
Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain (2009) 2.00
CD5 costimulation induces stable Th17 development by promoting IL-23R expression and sustained STAT3 activation. Blood (2011) 1.62
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland. MAbs (2011) 1.61
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature (2016) 1.52
Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol (2008) 1.43
CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proc Natl Acad Sci U S A (2007) 1.40
CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol (1999) 1.37
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol (2014) 1.36
CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. Mol Cell Biol (2006) 1.35
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol (2012) 1.30
Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood (2005) 1.30
Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness. Proc Natl Acad Sci U S A (1996) 1.29
Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol (2004) 1.27
Lymphocyte populations and immune responses in CD5-deficient mice. Eur J Immunol (1994) 1.25
Small molecule inhibitors of RORγt: targeting Th17 cells and other applications. Eur J Immunol (2012) 1.24
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med (2014) 1.23
The role of membrane-associated adaptors in T cell receptor signalling. Semin Immunol (2000) 1.21
Negative regulation of CD4 lineage development and responses by CD5. J Immunol (1999) 1.20
Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med (2010) 1.12
Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse. J Immunol (2007) 1.11
Quantitative proteomics analysis of signalosome dynamics in primary T cells identifies the surface receptor CD6 as a Lat adaptor-independent TCR signaling hub. Nat Immunol (2014) 1.07
CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol (2010) 1.04
Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1. Eur J Immunol (1999) 1.03
Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. Arthritis Rheum (1998) 1.03
The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation. J Immunol (2011) 1.01
Structures of CD6 and Its Ligand CD166 Give Insight into Their Interaction. Structure (2015) 1.00
Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J Immunol (2006) 1.00
miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORγt and STAT3. J Immunol (2014) 0.98
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. MAbs (2014) 0.97
The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains. J Immunol (2005) 0.96
CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol (2002) 0.96
Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia (2011) 0.94
Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology (1996) 0.93
Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol (2016) 0.93
CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur J Immunol (2011) 0.93
CD6 modulates thymocyte selection and peripheral T cell homeostasis. J Exp Med (2016) 0.92
Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. J Neuroimmunol (2010) 0.90
Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma (Larchmt) (2008) 0.89
Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses. Curr Drug Targets (2016) 0.89
Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome. J Autoimmun (2010) 0.89
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab. Curr Drug Targets (2016) 0.89
Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant (2014) 0.88
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases. Arthritis (2011) 0.87
CD6 as a potential target for treating multiple sclerosis. Proc Natl Acad Sci U S A (2017) 0.87
Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol (2015) 0.86
CD6 as a therapeutic target in autoimmune diseases: successes and challenges. BioDrugs (2013) 0.84
Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues. J Immunol (2004) 0.84
High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome. Rheumatology (Oxford) (2001) 0.84
ALCAM and CD6--multiple sclerosis risk factors. J Neuroimmunol (2014) 0.82
Akt phosphorylation and regulation of transketolase is a nodal point for amino acid control of purine synthesis. Mol Cell (2014) 0.82
Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy (2015) 0.80
Transcriptional regulation of CD6 expression on human T lymphocytes by phorbol ester. J Immunol (1994) 0.80
CD6 as a Cell Surface Receptor and As a Target for Regulating Immune Responses. Curr Drug Targets (2016) 0.79
Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study. Clin Rheumatol (2015) 0.78
Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor. Curr Drug Targets (2016) 0.78
T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1. J Immunol (2014) 0.77
Editorial: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis. Curr Drug Targets (2016) 0.76
High CD6 and low chemokine receptor expression on peripheral blood lymphocytes correlates with MRI gadolinium enhancement in MS. J Neuroimmunol (2014) 0.76
The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis. J Cutan Med Surg (2016) 0.76
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. PLoS One (2012) 0.75
Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis. Proc Natl Acad Sci U S A (2017) 0.75